VEGFD and colorectal cancer: Recently, it has been suggested that the therapeutic effect of VEGF/VEGFR2 inhibition in colorectal cancer patients, using an anti-VEGFR2 antibody (Ramucirumab), is linked to the concentration of VEGF-D in peripheral blood [29].